HDAC/mTOR Inhibitor Combination as Treatment for Prostate Cancer

April 8, 2014
Roberto Pili, MD

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.

Clinical Pearls:

  • There is an unmet need for a novel agent that has a direct effect on the survival pathway in prostate cancer
  • mTOR is one of the recognized pathways in prostate cancer and clinical data suggests mTOR inhibitors demonstrate activity in patients with prostate cancer
  • Combining mTOR and HDAC inhibitors may be a more effective way to develop an mTOR inhibitor